Localization and variation of TRAIL and its receptors in human placenta during gestation

Life Sciences

Volumn 74, Issue 12, 2004, Pages 1479-1486

  Chen, LiHua ^a   Liu, XueSong ^a   Zhu, Yong ^a   Cao, YunXin ^a   Sun, Lan ^a   Jin, BoQuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gestation; Human placenta; Immunohistochemistry; TRAIL TRAILR

Indexed keywords

TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CAPILLARY ENDOTHELIUM; CONTROLLED STUDY; CYTOTROPHOBLAST; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MICROSCOPY; PLACENTA; PREGNANCY; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; SYNCYTIOTROPHOBLAST;

EID: 0347914569     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2003.07.044     Document Type: Article

References (22)

1. Athanassakis I., Papadimitriou L., Koumantakis E., Vassiliadis S. Th1- and Th2-type lymphokine-assisted induction and release of chemokine receptors from primary human trophoblast cells. Human Immunology. 61(7):2000;651-657.
2. Cunningham D.S., Tichenor J.R. Jr. Decay-accelerating factor protects human trophoblast from complement-mediated attack. Clinical Immunology Immunopathology. 74(2):1995;156-161.
3. Dealtry G.B., Clark D.E., Sharkey A., Charnock-Jones D.S., Smith S.K. Expression and localization of the Th2-type cytokine interleukin-13 and its receptor in the placenta during human pregnancy. American Journal of Reproductive Immunology. 40(4):1998;283-290.
4. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7(6):1997;813-820.
5. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biological Chemistry. 273(23):1998;14363- 14367.
6. Golstein P. Cell death: TRAIL and its receptors. Current Biology. 7(12):1997;R750-R753.
7. Hammer A., Dohr G. Apoptotic nuclei within the uterine deciduas of first trimester pregnancy arise from CD45 positive leukocytes. American Journal of Reproductive Immunology. 42(2):1999;88-94.
8. Holmes C.H., Simpson K.L., Okada H., Okada N., Wainwright S.D., Purcell D.F., Houlihan J.M. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55). Europe Journal of Immunology. 22(6):1992;1579-1585.
9. Hunt, J.S., Hutter, H., 1996. Current theories on protection of the fetal semiallograft. In: HLA and the Maternal-Fetal Relationship (Eds.). Austin:Lan-des Pub. Co, pp. 27-45.
10. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104(4):2001;487-501.
11. MacFarlane M., Ahmad M., Srinivasula S.M., Fernandes-Alnemri T., Cohen G.M., Alnemri E.S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. Journal of Biological Chemistry. 272(41):1997;25417-25420.
12. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A.D., Godowski P., Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Current Biology. 7(12):1997;1003-1006.
13. Nagata S. Apoptosis by death factor. Cell. 88(3):1997;355-365.
14. Pan G., Ni J., Wei Y.F., Yu G.L., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277(5327):1997;815-818.
15. Pan G., Rourke K.O., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science. 276(5309):1997;111- 113.
16. Phillips T.A., Ni J., Pan G., Ruben S.M., Wei Y.F., Pace J.L., Hunt J.S. TRAIL (Apo-2L) and TRAIL receptors in human placentas: Implications for immune privilege. Journal of Immunology. 162(10):1999;6053-6059.
17. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry. 271(22):1996;12687- 12690.
18. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D., Ramakrishnan L., Gray C.L., Baker K., Wood W.I. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277(5327):1997;818-821.
19. Simon A.K., Willams O., Mongkolsapaya J., Jin B., Xu X., Walczak H., Screaton G. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proceedings of the National Academy of Sciences of the United States of America. 98(9):2001;5158-5163.
20. Takahashi N., Udagawa N., Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochemical and Biophysical Research Communication. 256(3):1999;449-455.
21. Weetman A.P. The immunology of pregnancy. Thyroid. 9(7):1999;643-646.
22. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3(6):1995;673-682.